Bisphosphonate treatment of tumor-induced hypercalcemia in a toddler: Case report and review of related literature

Endocrine Practice

Volumn 12, Issue 6, 2006, Pages 670-675

  Mastrandrea, Lucy D ^a   Albini, Christine H ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; PARATHYROID HORMONE RELATED PROTEIN;

CASE REPORT; DIFFERENTIAL DIAGNOSIS; HUMAN; HYPERCALCEMIA; KIDNEY TUMOR; MALE; PRESCHOOL CHILD; REVIEW; RHABDOID TUMOR;

CHILD, PRESCHOOL; DIAGNOSIS, DIFFERENTIAL; DIPHOSPHONATES; HUMANS; HYPERCALCEMIA; KIDNEY NEOPLASMS; MALE; PARATHYROID HORMONE-RELATED PROTEIN; RHABDOID TUMOR;

EID: 33847743466     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.12.6.670     Document Type: Article

References (24)

1. Vassilopoulou-Sellin R, Newmann BM, Taylor SH, Guinee VF. Incidence of hypercalcemia in patients with malignancy referred to a comprehensive cancer center. Cancer. 1993;71:1309-1312.
2. Ralston SH. Pathogenesis and management of cancer associated hypercalcemia. Cancer Surv. 1994;21:179-196.
3. McKay C, Furman WL. Hypercalcemia complicating childhood malignancies. Cancer. 1993;72:256-260.
4. Leblanc A, Caillaud JM, Hartmann O. Hypercalcemia preferentially occurs in unusual forms of childhood non-Hodgkin's lymphoma, rhabdomyosarcoma, and Wilms' tumor: a study of 11 cases. Cancer. 1984;54:2132-2136.
5. Harguindey S, DeCastro L, Barcos M, Getaz EP, Henderson ES, Freeman A. Hypercalcemia complicating childhood malignancies: a report of seven cases with some pathophysiological considerations. Cancer. 1979;44:2280-2290.
6. Kutluk MT, Hazar V, Akyuz C, Varan A, Buyukpamukcu M. Childhood cancer and hypercalcemia: report of a case treated with pamidronate. J Pediatr. 1997;130:828-831.
7. Lteif AN, Zimmerman D. Bisphosphonates for treatment of childhood hypercalcemia. Pediatrics. 1998;102(4 Pt 1):990-993.
8. Young G, Shende A. Use of pamidronate in the management of acute cancer-related hypercalcemia in children. Med Pediatr Oncol. 1998;30:117-121.
9. Kerdudo C, Aerts I, Fattet S, et al. Hypercalcemia and childhood cancer: a 7-year experience. J Pediatr Hematol Oncol. 2005;27:23-27.
10. Claudius IA, Fattal O, Nakamoto J. Hypercalcemia. emedicine. Update January 16, 2004. Available at: http://www.emedicine.com/ped/topic1062. htm. Accessed for verification March 9, 2006.
11. Allgrove J. Bisphosphonates. Arch Dis Child. 1997;76:73-75.
12. Adamson BB, Gallacher SJ, Byars J, Ralston SH, Boyle IT, Boyce BF. Mineralisation defects with pamidronate therapy for Paget's disease. Lancet. 1993;342:1459-1460.
13. Brumsen C, Hamdy NA, Papapoulos SE. Long-term effects of bisphosphonates on the growing skeleton: studies of young patients with severe osteoporosis. Medicine (Baltimore). 1997;76:266-283.
14. Clark C. Osteogenesis imperfecta: an overview. Nurs Stand. 2001;16:47-52.
15. Byers PH. Osteogenesis imperfecta: perspectives and opportunities. Curr Opin Pediatr. 2000;12:603-609.
16. Plotkin H, Rauch F, Bishop NJ, et al. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab. 2000;85:1846-1850.
17. Åström E, Söderhäll S. Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child. 2002;86:356-364.
18. Falk MJ, Heeger S, Lynch KA, et al. Intravenous bisphosphonate therapy in children with osteogenesis imperfecta. Pediatrics. 2003;111:573-578.
19. Munns CF, Rauch F, Travers R, Glorieux FH. Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: clinical and histomorphometric outcome. J Bone Miner Res. 2005;20:1235-1243.
20. Liens D, Delmas PD, Meunier PJ. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. Lancet. 1994;343:953-954.
21. Robinson RE, Nahata MC, Hayes JR, Batisky DL, Bates CM, Mahan JD. Effectiveness of pretreatment in decreasing adverse events associated with pamidronate in children and adolescents. Pharmacotherapy. 2004;24:195-197.
22. Bergqvist D. Venous thromboembolism in cancer patients: expanding horizons. Semin Thromb Hemost. 2002;28(Suppl 3):19-23.
23. Naschitz JE, Yeshurun D, Eldar S, Lev LM. Diagnosis of cancer-associated vascular disorders. Cancer. 1996;77:1759-1767.
24. Nussbaum SR, Younger J, Vandepol CJ, et al. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. Am J Med. 1993;95:297-304.